Bone Biologics Statistics Share Statistics Bone Biologics has 1.61M
shares outstanding. The number of shares has increased by -0.14%
in one year.
Shares Outstanding 1.61M Shares Change (YoY) -0.14% Shares Change (QoQ) -0.18% Owned by Institutions (%) 0.82% Shares Floating 1.79M Failed to Deliver (FTD) Shares 6,720 FTD / Avg. Volume 1.31%
Short Selling Information The latest short interest is 29.61K, so 1.84% of the outstanding
shares have been sold short.
Short Interest 29.61K Short % of Shares Out 1.84% Short % of Float 1.85% Short Ratio (days to cover) 1
Valuation Ratios The PE ratio is -2.08 and the forward
PE ratio is -1.2.
Bone Biologics's PEG ratio is
0.02.
PE Ratio -2.08 Forward PE -1.2 PS Ratio 0 Forward PS n/a PB Ratio 2.46 P/FCF Ratio -2.07 PEG Ratio 0.02
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for Bone Biologics.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 10.22,
with a Debt / Equity ratio of 0.
Current Ratio 10.22 Quick Ratio 10.22 Debt / Equity 0 Debt / EBITDA n/a Debt / FCF n/a Interest Coverage 0
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee n/a Profits Per Employee $-2.06M Employee Count 2 Asset Turnover 0 Inventory Turnover n/a
Taxes Income Tax n/a Effective Tax Rate 0%
Stock Price Statistics The stock price has increased by -61.69% in the
last 52 weeks. The beta is 1.3, so Bone Biologics's
price volatility has been higher than the market average.
Beta 1.3 52-Week Price Change -61.69% 50-Day Moving Average 2.79 200-Day Moving Average 4.89 Relative Strength Index (RSI) 62.83 Average Volume (20 Days) 511,306
Income Statement
Revenue n/a Gross Profit n/a Operating Income -4.22M Net Income -4.11M EBITDA -4.11M EBIT -4.11M Earnings Per Share (EPS) -4.83
Full Income Statement Balance Sheet The company has 3.33M in cash and 0 in
debt, giving a net cash position of 3.33M.
Cash & Cash Equivalents 3.33M Total Debt n/a Net Cash n/a Retained Earnings -85.02M Total Assets 7M Working Capital 6.6M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -4.12M
and capital expenditures -5, giving a free cash flow of -4.12M.
Operating Cash Flow -4.12M Capital Expenditures -5 Free Cash Flow -4.12M FCF Per Share -2.72
Full Cash Flow Statement Margins
Gross Margin n/a Operating Margin n/a Pretax Margin n/a Profit Margin n/a EBITDA Margin n/a EBIT Margin n/a FCF Margin n/a
Dividends & Yields BBLG does not appear to pay any dividends at this time.
Dividend Per Share n/a Dividend Yield n/a Dividend Growth (YoY) n/a Payout Ratio n/a Earnings Yield n/a FCF Yield n/a
Dividend Details Analyst Forecast Currently there are no analyst rating for BBLG.
Price Target n/a Price Target Difference n/a Analyst Consensus n/a Analyst Count n/a
Stock Forecasts Fair Value There are several formulas that can be used to estimate the
intrinsic value of a stock.
Lynch Fair Value n/a Lynch Upside n/a Graham Number n/a Graham Upside n/a
Stock Splits The last stock split was on Jun 10, 2025. It was a
backward
split with a ratio of 1:6.
Last Split Date Jun 10, 2025 Split Type backward Split Ratio 1:6
Scores Altman Z-Score -13.6 Piotroski F-Score 3
